Cancer ranks second only to heart disease as a leading cause of death in the United States, making it a tremendous burden in years of life lost, patient suffering, and economic costs. Fulfilling the Potential for Cancer Prevention and Early Detection reviews the proof that we can dramatically reduce cancer rates. The National Cancer Policy Board, part of the Institute of Medicine, outlines a national strategy to realize the promise of cancer prevention and early detection, including specific and wide-ranging recommendations. Offering a wealth of information and directly addressing major controversies, the book includes: A detailed look at how significantly cancer could be reduced through lifestyle changes, evaluating approaches used to alter eating, smoking, and exercise habits. An analysis of the intuitive notion that screening for cancer leads to improved health outcomes, including a discussion of screening methods, potential risks, and current recommendations. An examination of cancer prevention and control opportunities in primary health care delivery settings, including a review of interventions aimed at improving provider performance. Reviews of professional education and training programs, research trends and opportunities, and federal programs that support cancer prevention and early detection. This in-depth volume will be of interest to policy analysts, cancer and public health specialists, health care administrators and providers, researchers, insurers, medical journalists, and patient advocates.

Most women who die from cervical cancer, particularly in developing countries, are in the prime of their life. They may be raising children, caring for their family, and contributing to the social and economic life of their town or village. Their death is both a personal tragedy, and a sad and unnecessary loss to their family and their community. Unnecessary, because there is compelling evidence, as this Guide makes clear, that cervical cancer is one of the most preventable and treatable forms of cancer, as long as it is detected early and managed effectively. Unfortunately, the majority of women in developing countries still do not have access to cervical cancer prevention programmes. The consequence is that, often, cervical cancer is not detected until it is too late to be cured. An urgent effort is required if this situation is to be corrected. This Guide is intended to help those responsible for providing services aimed at reducing the burden posed by cervical cancer for women, communities and health systems. It focuses on the knowledge and skills needed by health care providers, at different levels of care.

Recoge: 1. Epidemiological guidelines for quality assurance in cervical cancer screening - 2. Methods for screening and diagnosis - 3. Laboratory guidelines and quality assurance practices for cytology - 4. Techniques and quality assurance guidelines for histopathology - 5. Management of abnormal cervical cytology - 6. Key performance indicators - 7. Annexes.

Cervical cancer is one of the most frequently occurring cancers among women in sub-Saharan Africa (SSA). While preventable if detected early, many women experience challenges accessing life-saving screening and treatment due to health systems inefficiencies, costs, perceptions of screening, and time required to seek care. Integration of cervical cancer screening into existing public health programs, such as screening women as they enter the health system for HIV treatment or bring their children to obtain routine immunizations, may increase screening coverage rates at low marginal costs. This dissertation aimed to evaluate the potential costs, cost-effectiveness, and budget impact of integrating cervical cancer screening into a routine childhood immunization clinic in Uganda and an HIV-treatment facility in Kenya. First, using primary facility-level data, a model-based analysis was conducted to estimate the individual level-costs of treatment for pre-cancerous lesions, cervical cancer, and cervical cancer palliative care in Kenya. Second, a Markov model was developed to assess the potential costeffectiveness of integrating screening programs into an HIV treatment clinic in Kenya and a routine childhood immunization clinic in Uganda. Third, a budget impact model estimated the size of the target population and potential uptake of screening, as well as the impact on the current health system, of each integration strategy. Study findings indicate that integrating cervical cancer screening into existing health systems in East Africa is likely to be cost-saving or cost-effective in terms of cost-per life year saved, compared to current strategies of nonintegrated screening. These findings provide decision-makers in Kenya, Uganda, and other similar LMICs with information on the costs and cost-effectiveness of innovative methods for increasing access to life-saving cervical cancer screening and treatment interventions.

This dissertation, "Cost-effectiveness of Primary HPV Testing for Cervical Cancer Screening: a Systematic Review" by Ka-man, Choi, 蔡嘉敏, was obtained from The University of Hong Kong (Pokfulam, Hong Kong) and is being sold pursuant to Creative Commons: Attribution 3.0 Hong Kong License. The content of this dissertation has not been altered in any way. We have altered the formatting in order to facilitate the ease of printing and reading of the dissertation. All rights not granted by the above license are retained by the author. Abstract: Background: Human papillomavirus (HPV) DNA test is more sensitive and can detect more high-grade cervical intraepithelial lesions than cytology test in cervical cancer screening. There are studies confirming HPV test being more effective in cervical cancer screening by detecting the persistence of HPV infection that could lead to cancer. However, the costs associated with a HPV test is higher than a cytology test. Moreover, HPV test is less specific which could subject more women to further triage tests or unnecessary invasive diagnostic procedures. Therefore healthcare costs could possibly increase if primary HPV screening is to be adopted. Study objective: The aim of the study is to systematically review the cost-effectiveness of primary HPV testing in cervical cancer screening Method: Electronic search was performed in three biomedical databases (PubMed, Medline, Cochrane Library) and one economic evaluation database to identify relevant studies. Studies were selected according to the explicit inclusion and exclusion criteria defined. Only those studies carried out in high-income countries were included so that result could be better applied to Hong Kong. Results: A total of 19 studies were included in this systematic review. Cytology-only method is generally not cost-effective. To be cost-effective, it has to be performed in a longer screening interval which would reduce not only the screening costs but also a reduction in the health outcomes. Among the different options in HPV-based primary screening, HPV testing with cytology triage is the most cost-effective strategy in many of the studies. Combined HPV/cytology co-screening could achieve the biggest health benefit but is also most costly. HPV-based screening is more cost-effective for those >30 years of age and is usually less cost-effective if applied to young women. From the result in sensitivity analysis, HPV-based screening is sensitive to an increase in the costs of the HPV test, a low HPV test sensitivity and a low screening compliance rate. Conclusion: Primary HPV screening is cost-effective and generally performs better than cytology screening. The result of this systematic review guides the future direction of developing an optimal cervical screening strategy in Hong Kong. Local context has to be considered when examining the cost-effectiveness of primary HPV testing for cervical screening. Good quality local epidemiological data on HPV infection and cervical cancer and screening would be required to aid future research on the application of HPV test for cervical cancer screening in Hong Kong. DOI: 10.5353/th_b5098438 Subjects: Medical screening Cervix uteri - Cancer - Diagnosis